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Background: The phylogenetically highly conserved CK1 protein kinases consisting of at least seven isoforms form
a distinct family within the eukaryotic protein kinases. CK1 family members play crucial roles in a wide range of
signaling activities. However, the functional role of CK1 in somatosensory pain signaling has not yet been fully
understood. The aim of this study was to clarify the role of CK1 in the regulation of inflammatory pain in mouse
carrageenan and complete Freund’s adjuvant (CFA) models.
Results: We have used two structurally different CK1 inhibitors, TG003 and IC261. TG003, which was originally
identified as a cdc2-like kinase inhibitor, had potent inhibitory effects on CK1 isoforms in vitro and in cultured cells.
Intrathecal injection of either TG003 (1-100 pmol) or IC261 (0.1-1 nmol) dose-dependently decreased mechanical
allodynia and thermal hyperalgesia induced by carrageenan or CFA. Bath-application of either TG003 (1 μM) or
IC261 (1 μM) had only marginal effects on spontaneous excitatory postsynaptic currents (sEPSCs) recorded in the
substantia gelatinosa neurons of control mice. However, both compounds decreased the frequency of sEPSCs in
both inflammatory pain models.
Conclusions: These results suggest that CK1 plays an important pathophysiological role in spinal inflammatory pain
transmission, and that inhibition of the CK1 activity may provide a novel strategy for the treatment of inflammatory
pain.
Keywords: Allodynia, Carrageenan, Complete Freund’s adjuvant, CFA, Hyperalgesia, Whole-cell patch-clampBackground
Increased sensitivity to both noxious and non-noxious
stimuli is a hallmark of persistent pain states following
tissue injury and inflammation. This hypersensitivity is
associated with both peripheral and spinal neuronal
plasticities, leading to a reduction of activation threshold
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unless otherwise stated.root ganglion (DRG) and trigeminal ganglion, as well as
an increase in the synaptic activity between sensory
nerve endings and second-order neurons in the spinal
dorsal horn [1-3]. Inflammatory pain is typically treated
with opioids and non-steroidal anti-inflammatory drugs
such as cyclooxygenase 2 inhibitors. However, these
treatments are currently limited by well-known side ef-
fects. Acute opioid treatment produces respiratory de-
pression, sedation, nausea, constipation and vomiting,
and long-term treatment with opioids and cyclooxygen-
ase 2 inhibitors is associated with the development of
addiction and cardiovascular defects, respectively. Thus,
chronic pain associated with inflammation is still diffi-
cult to treat, and development of new strategies leadingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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eagerly awaited.
Casein kinases (CK) were one of the first serine/threo-
nine protein kinases to be identified and characterized in
the 1970s [4-7]. Two distinct CK activities were recog-
nized, leading to the identification of two different ki-
nases, CK1 and CK2. Whereas CK2 belongs to the
CMGC (cyclin-dependent kinase, mitogen-activated pro-
tein kinase, glycogen synthase kinase, CDC-like kinase)
group, CK1 forms one of the eight major groups of pro-
tein kinases identified in the human and mouse genomes
[8,9]. The CK1 family consists of several isoforms that
include CK1α, CK1γ1-CK1γ3, CK1δ, and CK1ε and their
various splice variants. CK1 is present in different cell
types and in subcellular compartments, including the
plasma membrane, cytosol, and nucleus. The widespread
distribution of CK1 suggests important regulatory roles
of this protein kinase. At present, CK1 has been impli-
cated in diverse biological processes including circadian
rhythms, membrane trafficking, cytoskeleton mainten-
ance, DNA and RNA metabolism [4-6]. However, the
function of CK1 in the somatosensory pathway has not
yet been fully examined.
IC261 is a commonly used and commercially available
CK1 inhibitor, which is reported to be relatively specific
for CK1δ and ε isoforms [10], although some of its ef-
fects are likely to be independent from CK1 inhibition
[11]. Previously we demonstrated that intrathecal admin-
istration of IC261 effectively reversed neuropathic pain-
like behavior in mice [12]. TG003 originally identified as
a cdc2-like kinase (Clk) inhibitor [13,14], has recently
been shown to inhibit CK1δ and ε activities equally to,
or more potently than IC261 in vitro [15,16]. In this
study, we examined the effects of these two structurally
different CK1 specific inhibitors on inflammatory pain
induced by peripheral treatment of carrageenan or CFA.
A preliminary report of this study has been presented
elsewhere [17].
Results
Evaluation of TG003 as an inhibitor of CK1 family
members
We first verified the inhibitory effect of TG003 on the
enzymatic activity of CK 1 family members and com-
pared it with that of IC261. Recombinant CK1α, δ, ε, γ1,
γ2 or γ3 were incubated with the substrate peptide
CKtide in the presence of different concentrations of
TG003 or IC261, respectively. Both small molecules
inhibited CK1 family members in a dose-dependent
manner (Figure 1). Inhibition of CK1α, δ and ε by
TG003 were equivalent to that by IC261. On the other
hand, the inhibitory activities of TG003 on the kinase
activity of CK1γ1, γ2 and γ3 were 20-fold or more
higher than those of IC261 (Figure 1). These resultsindicate that TG003 and IC261 are able to suppress the
kinase activity of broad CK1 family members equally.
TG003 inhibited CK1δ and ε-induced nuclear translocation
of PER3
We next examined whether TG003 inhibits CK1δ and ε
in living cells. To quantify the kinase activity of CK1δ
and ε, we utilized CK1-induced nuclear translocation of
PER3. PER3 is one of the mammalian homologue of
period, which is a core molecular component of circa-
dian rhythm and is involved in transcription-translation
oscillatory feedback loops on the molecular level in the
hypothalamic suprachiasmatic nucleus, the master pace-
maker regulating circadian rhythms [4,18]. Phosphoryl-
ation of PER3 by CK1δ and/or CK1ε in the cytoplasm
induces their translocation to the nucleus [19]. We con-
structed a constitutive expression vector of PER3 fused
with mCherry (mCherry-PER3), and cloned both CK1δ
and CK1ε under control of a doxycycline-inducible pro-
moter. HEK293 cells were transfected with these recom-
binant vectors, and stable cell lines expressing both
mCherry-PER3 and CK1 were established (Figure 2A,
B). In the absence of doxycycline, fluorescence signals of
mCherry-PER3 were mainly detected in the cytoplasm.
Treatment with doxycycline for 8 hours, which triggered
the expression of CK1δ and ε, respectively, induced nu-
clear accumulation of mCherry-PER3. Co-administration
of TG003 with doxycycline inhibited the nuclear trans-
location of mCherry-PER3. Similarly, the CK1 specific
small molecule inhibitor, PF-670462, which was used as
positive control [20], also inhibited the nuclear trans-
location (Figure 2A, B). On the other hand, a structurally
similar compound TG001 [13], which possesses no in-
hibitory effect on CK1δ and ε in the in vitro assay (data
not shown), did not prevent the nuclear translocation of
mCherry-PER3. To quantify the inhibitory effects on the
nuclear translocation, we measured the fluorescence in-
tensities of mCherry in the nucleus and cytoplasm by
compartmental analysis using Cellomics BioApplications
software for 20 images of each one, and calculated the
mCherry-PER3 nuclear/cytoplasmic ratio as described in
Methods. The ratio was significantly decreased upon
TG003 or PF-670462, compared to that upon TG001 or
vehicle treatment (Figure 2C, D), indicating that TG003
inhibits the function of CK1δ and ε in living cells.
Intrathecal injection of IC261 or TG003 attenuated acute
and persistent inflammatory pain behaviors
To investigate whether CK1 is involved in the inflamma-
tory pain states, we evaluated the effects of IC261 or
TG003 in mouse models of inflammatory pain. I.t. injec-
tions of IC261 (0.1-1 nmol) or TG003 (0.1-100 pmol)
dose-dependently increased both withdrawal threshold
and withdrawal latency of the hind paw ipsilateral to
Figure 1 TG003 suppresses kinase activity of CK1 family members in vitro. Recombinant CK1 family members were incubated with the
substrate peptide CKtide in the presence of different concentrations of TG003 and IC261. TG003 (open circle) and IC261 (closed square) inhibited
CK1 family members in a dose-dependent manner. The IC50 values of TG003 on the kinase activity of CK1α, δ, ε, γ1, γ2 and γ3were 0.33, 0.34, 1.4,
1.5, 0.93 and 0.88 μM, respectively. The IC50 values of IC261 were 0.19, 0.60, 0.86, > 30, > 30 and > 30 μM, respectively. Representative dose-response
curves with Hill slope are shown. The results are presented as an average of duplicated experiments.
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and 4). Spinal preemptive treatment of IC261 also dose-
dependently attenuated the development of thermal
hyperalgesia induced by carrageenan (Figure 3B). Thus,
blocking the CK1 activity at the spinal level appeared to
be effective in reduction of inflammation-induced mech-
anical allodynia and thermal hyperalgesia. The max-
imum effects were observed 0.5-1 hour after the
injections of both inhibitors and significant analgesic ef-
fects were still observed 3-4 hours after the injection of
the highest doses used in this study (Figures 3 and 4).
These inhibitors had no significant effects on the contra-
lateral hind paw (Figures 3 and 4). I.t. injection of ve-
hicle (1% DMSO in saline) used as a solvent for the
drugs did not show any effects (Figures 3A and 4B, data
not shown).
Carrageenan- and CFA-induced inflammation did not
upregulate CK1α, δ and ε protein expression
We next examined the protein expression levels of
CK1α, δ and ε protein in the spinal cord (L4-6) and
DRGs (L4-6) by immunoblot analyses. Expression of the
three CK1 isoforms were not significantly altered in both
spinal cord (carrageenan model: CK1α, 95.6 ± 11.2%
of control, n = 6; CK1δ, 143.4 ± 25.0%, n = 11; CK1ε,
101.7 ± 9.25%, n = 6; CFA model : CK1α, 108.7 ± 18.3%,
n = 6; CK1δ, 99.7 ± 13.7%, n = 11; CK1ε, 93.6 ± 10.8%,n = 6) and DRGs (carrageenan model: CK1α, 111.4 ±
23.2% of control, n = 6; CK1δ, 125.4 ± 33.4%, n = 7; CK1ε,
109.8 ± 23.1%, n = 6; CFA model: CK1α, 92.4 ± 18.3% of
control, n = 6; CK1δ, 102.2 ± 4.99%, n = 7; CK1ε, 96.8 ±
11.0%, n = 6) after carrageenan (6 hours)- or CFA
(3 days)-treatment, respectively (see also Additional file 1).
IC261 and TG003 decreased the frequency of sEPSCs in
inflammatory pain model mice
To explore the mechanism of the antinociception in-
duced by IC261 or TG003 at the spinal level, we pre-
pared L5 spinal cord slice preparation from adult mice
(7-10 weeks old) and performed patch-clamp recordings
in lamina II SG neurons ipsilateral to carrageenan, CFA,
or vehicle injection [21-23]. The SG neurons of the
spinal dorsal horn play an important role in the trans-
mission and modulation of nociceptive information from
the periphery to the CNS [24-26], and is one of the key
sites generating synaptic plasticity (central sensitization)
after tissue injury [3,26,27]. Such plasticity is exhibited in
part as changes in spontaneous excitatory and inhibitory
postsynaptic currents (sEPSCs and sIPSCs, respectively),
which could point out both presynaptic mechanisms (fre-
quency changes) and postsynaptic mechanisms (amplitude
changes) [28-32].
We first examined the passive membrane properties
of SG neurons. All SG neurons examined had resting
Figure 2 TG003 inhibits CK1δ/ε-induced nuclear translocation of PER3. (A, B) Localization of mCherry-PER3 in HEK293 cells expressing CK1δ
(A) or CK1ε (B). Prior to doxycycline (Dox)-induced expression of CK1δ/ε for 8 hours, the cells were treated with vehicle control, TG003, TG001, or
PF-670462 for 1 hour. The treated cells were fixed and stained with Hoechst33342 to define nucleus. Representative images are shown. (C, D).
Quantification of the nuclear/cytoplasmic fluorescence intensity ratio. The data are mean ± SEM (n = 20). #P < 0.0001 (Student’s t-test).
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inflammatory pain model mice. No differences were found
in the resting membrane potential and input membrane
resistance among the groups (Additional file 2).
Next we characterized sEPSCs, recorded under voltage-
clamp at a holding potential of -70 mV, from control and
inflamed mice (Additional file 3A). The mean amplitude of
sEPSCs was not significantly different among the groups.
The mean frequency of sEPSCs, on the other hand, wassignificantly different. We found that the average frequency
but not the amplitude of sEPSCs was significantly in-
creased in mice inflamed with CFA 3 days before, al-
though carrageenan inflammation did not increase both
the average sEPSC frequency and amplitude 6 hours
after the injection.
We further examined sIPSCs from control and in-
flamed mice SG neurons at holding potentials of 0 mV
(Additional file 3B). Although the mean amplitude of
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Figure 3 Effects of CK1 inhibitors on carrageenan-induced acute inflammatory pain behaviors. (A, B) Effects of intrathecal injection of
IC261 on carrageenan (Car)-induced thermal hyperalgesia. IC261 was injected 5 hour after (A) or 30 min before (B) carrageenan injection. (C, D)
Effects of intrathecal injection of TG003 on carrageenan (Car)-induced mechanical allodynia (C) and thermal hyperalgesia (D). Paw withdrawal
threshold to mechanical stimulation and paw withdrawal latency to thermal stimuli are plotted against the time after carrageenan injection into a
hindpaw. Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, compared with pre-drug data (one-way ANOVA followed by Dunnett’s post
hoc test).
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frequency of sIPSCs was significantly reduced in CFA
groups.
We then examined the possibility that the observed ef-
fects of the two CK1 inhibitors originate from the regula-
tion of the excitatory and inhibitory synaptic transmission
in lamina II of inflamed mice. Superfusion of spinal cord
slices from control mice either treated with IC261 (1 μM)
or TG003 (1 μM) altered neither the frequency nor the
amplitude of sEPSCs (Figures 5A and 6A). However, both
CK1 inhibitors significantly suppressed sEPSCs recorded
from carrageenan (Figures 5B and 6B)- or CFA (Figures 5C
and 6C)-treated mice. It should be noted, however,
that the inhibitory effects on sEPSC frequencies were
much more dramatic than those on sEPSC amplitudes
(Figures 5D and 6D), and furthermore, the magnitudeof inhibitory effects induced by TG003 on sEPSC frequen-
cies was significantly higher than that induced by IC261
(Figures 5D and 6D) in both carrageenan and CFA treated
animals. On the other hand, IC261 (1 μM) did not affect
sIPSCs from the inflamed mice, although slight but signifi-
cant reduction of the mean amplitude of control sIPSCs
was observed (Figure 7).
Discussion
The present study showed for the first time that the two
structurally different CK1 inhibitors effectively reversed
mechanical allodynia and thermal hyperalgesia induced
by acute or persistent hindpaw inflammation. From
in vitro whole-cell patch-clamp studies, a part of the an-
algesic mechanisms was suggested to be due to the in-
hibitory effects of the CK1 inhibitors on excitatory
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Figure 4 Effects of CK1 inhibitors on CFA-induced persistent inflammatory pain behaviors. (A, B) Effects of intrathecal injection of IC261
on CFA-induced mechanical allodynia (A) and thermal hyperalgesia (B). (C, D) Effects of intrathecal injection of TG003 on CFA-induced mechanical
allodynia (C) and thermal hyperalgesia (D). Paw withdrawal threshold to mechanical stimulation and paw withdrawal latency to thermal stimuli are
plotted against the time after intrathecal injection into IC261 or TG003. CFA was injected 3 days before. Data are mean ± SEM. *P < 0.05, **P < 0.01,
***P < 0.001, compared with pre-drug (at 0 hour) data (one-way ANOVA followed by Dunnett’s post hoc test).
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mice.
Pharmacological properties of IC261 and TG003
In this study we clarified that both IC261 and TG003
equally blocked CK1α, δ and ε activities. We also identi-
fied that TG003 effectively blocked activities of CK1γ
isoforms. IC261 was initially reported as a selective
CK1δ/ε inhibitor which blocked CK1δ and ε enzymatic
activities more potently than CK1α activity [10]. How-
ever, our in vitro kinase assay and a recent report [16]
indicated that IC261 exerted comparable inhibitory ef-
fects against CK1α, δ and ε isoforms, but inhibitory ef-
fects on three CK1γ isoforms were relatively weak. In
contrast, TG003 demonstrated almost equal inhibitory
effects among CK1 isoforms. Results from our prelimin-
ary screening experiments and reports from other
groups [15,16] suggested that common targets for IC261
and TG003 are CK1α, δ and ε at this moment. Althoughrelative importance of each CK1 isoform in the allodynia
and hyperalgesia remains to be determined, CK1 might
play an important role for the development and main-
tenance of inflammatory pain.
One important finding of this study is that TG003
produced antinociceptive effects on both carrageenan-
and CFA-induced inflammatory pain models at lower
doses than IC261. This difference may be due to the fact
that TG003 also blocks CK1γ isoforms and Clks. In par-
ticular, IC50 values of TG003 against Clk1 and 4 iso-
forms (15-20 nM) [13] are smaller than those against
CK1 isoforms. However, it remains to be determined
whether activation of CK1γ isoforms and/or Clks signifi-
cantly contributes to the pathogenic mechanism of pain.
In addition, we could not exclude the possibility that
other CK1-independent effects of TG003 and/or IC261
might affect the antinociceptive effects.
It would be noteworthy that TG003 preferentially alle-
viated mechanical allodynia than thermal hyperalgesia in
Figure 5 IC261 decreased the mean frequency and amplitude of sEPSCs in inflammatory pain model mice. Representative traces of
sEPSCs in SG neurons of the spinal cord slices from naïve control (A), carrageenan (B)- and CFA (C)-inflamed mice showing the effects of IC261
(1 μM). Lower five traces represent sEPSCs at five given points in time presented above the upper trace, and are shown in an expanded time
scale. (D) Summary of results, testing the effects of IC261 on the sEPSC frequencies and amplitudes The percentage compared to pre-drug re-
sponse (as 100%) was shown as% control. *P < 0.05, **P < 0.01, compared with pretreatment control (Student’s t test).
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TG003 did not affect CFA-induced thermal hyperalgesia,
the same dosage of TG003 significantly reversed CFA-
induced mechanical allodynia. IC261, on the other hand,
was shown to be equally effective on both mechanical
allodynia and thermal hyperalgesia in the present inflam-
matory pain models, as well as in our previously de-
scribed spinal nerve injury model [12]. The reason of
this difference is currently unknown and further rigor-
ous studies would be necessary to evaluate the pharma-
cological profiles of TG003 and IC261.
Inhibition of pain-related synaptic plasticity by the CK1
inhibitors
Since intrathecal injection of these CK1 inhibitors re-
versed both mechanical and thermal nociceptive behaviors
after peripheral inflammation, we investigated whether
bath application of these CK1 inhibitors affects on sEPSCs
and/or sIPSCs by using the whole-cell patch-clamp
method in SG neurons of adult spinal cord slices.First, we characterized the effects of carrageenan- or
CFA-induced peripheral inflammation on the sEPSCs and
sIPSCs. In general accordance with previous reports
[28,33,34], we found that CFA inflammation for 3 days
elicited significant increase in mean frequency of sEPSCs,
and significant decrease of mean frequency, but not ampli-
tude, of sIPSCs. In contrast, significant changes in frequen-
cies and amplitudes of sEPSCs and sIPSCs were not
observed 6 hours after carrageenan injection, which may be
consistent with the previous report showing no alteration
in frequencies and amplitudes of miniature EPSCs and
IPSCs 1-2 days after carrageenan inflammation in imma-
ture rats [35]. One apparent difference between our present
data and the previous report using mice CFA model [28] is
that we could not detect significant increase in the mean
amplitude of sEPSCs after CFA inflammation. The reason
for this difference is at present unknown, but this might
be due to the difference (this study vs. [28]) of strain
(C57BL6/J vs. CD1), age (7-10 weeks old vs. 4-6 weeks old)
or duration after CFA injection (3 days vs. 1 day).
Figure 6 TG003 decreased the mean frequency, but not the amplitude of sEPSCs in inflammatory pain model mice. Representative
traces of sEPSCs in SG neurons of the spinal cord slices from naïve control (A), carrageenan (B)- and CFA (C)-inflamed mice showing the effects
of TG003 (1 μM). Lower five traces represent sEPSCs at five given points in time presented above the upper trace, and are shown in an expanded
time scale. (D) Summary of results, testing the effects of TG003 on the sEPSC frequencies and amplitudes. The percentage compared to pre-drug
response (as 100%) was shown as % control. **P < 0.01, compared with pretreatment control; #P < 0.05, compared with the effect of IC261 (see Figure 5)
(Student’s t test).
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IC261 or TG003 had no effects on sEPSCs from control
animals, but carrageenan and CFA inflammation turned
the CK1 inhibitors effective in decreasing the mean fre-
quencies of their respective sEPSCs. Since we did not
characterize the SG neurons we recorded by anatomical
and more detailed electrophysiological criteria [36,37] in
this study, it is currently difficult to discuss possible in-
volvement of CK1 in the superficial dorsal horn synaptic
circuits. However, it may be worth noting here that both
IC261 and TG003 exerted relatively consistent inhibitory
effects on sEPSCs in the inflammatory pain models. In
any case, this observation suggests that the nature of
sEPSCs recorded in inflamed mice seems to be very dif-
ferent from those found in control animals. Our previ-
ous report also demonstrated similar specific inhibitory
effects of IC261 on excitatory responses in dorsal horn
elicited by dorsal root electrical stimulation only in
spinal nerve injured but not in sham operated mice [12].
These results also seem to be consistent with the facts
that these CK1 inhibitors dampen inflammatory (thisstudy) and neuropathic (our previous study) pain-like
behaviors without showing any appreciable effects on
contralateral hindpaws.
Interestingly, we noticed a significant difference between
IC261 and TG003 on inflamed mice, that is, 1 μM of
TG003 had more potently inhibited the mean frequency of
sEPSCs than the same concentration of IC261. At present,
we could only speculate that the difference in their poten-
cies might be derived from the distinct actions of TG003
on CK1 isoforms and/or Clks as described above, but fur-
ther study is needed to verify this possibility.
The preferential inhibitory effects of IC261 and TG003
on the frequency of sEPSCs might suggest pre- rather
than post-synaptic site of action of these molecules in
SG synapses and this inhibitory modulation would con-
tribute the antinociceptive effects on inflamed mice. It is
generally believed that changes in the frequency and
amplitude of sEPSCs are mediated by respective pre-
and post-synaptic mechanisms [28-32]. We previously
suggested that similar mechanism would be involved in
the antinociceptive effects of CK1 inhibitors on neuropathic
Figure 7 IC261 had no effects on the sIPSCs in inflammatory pain model mice. Representative traces of sIPSCs in SG neurons of the spinal
cord slices from naïve control (A), carrageenan (B)- and CFA (C)-inflamed mice showing the effects of 1 μM IC261. Lower five traces represent
sIPSCs at five given points in time presented above the upper trace, and are shown in an expanded time scale. (D) Summary of results, testing
the effects of IC261 on the mean frequencies and amplitudes of sIPSCs. The percentage compared to pre-drug response (as 100%) was shown as
% control. **P < 0.01, compared with pretreatment control (Student’s t test).
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be associated with cytosolic vesicles including small syn-
aptic vesicles and to phosphorylate several small synaptic
vesicle-associated proteins in neuronal cells [38-40], sug-
gesting a possible involvement of CK1 in the synaptic
vesicle exocytosis [5,40].
At least CK1δ [41] and ε [12,42] proteins are shown to be
expressed in mouse spinal dorsal horn neurons and pri-
mary sensory neurons at normal state. In contrast to our
previous results that upregulation of CK1ε protein ex-
pression was observed in the spinal dorsal horn (L5)
and injured L5 DRG neurons ipsilateral to the nerve in-
jury in the mouse L5/6 spinal nerve injury model [12],
we could not detect significant increases of protein expres-
sion levels of CK1α, δ, ε isoforms in the spinal cord (L4-6)
and DRGs (L4-6) in the present immunoblot study as
shown in Additional file 1. It would be, therefore, interest-
ing to hypothesize that activity of CK1 in the primary sen-
sory neurons and/or spinal dorsal horn neurons regulated
by the peripheral inflammation would contribute to thespinal plasticity which has an important role in generating
inflammatory pain states. Several mechanisms, such as con-
trol of subcellular localization by regulating membrane
and/or nuclear trafficking, and modulation of the inhibitory
autophosphorylation sites located at C-terminal domains of
CK1, which have been identified to modulate CK1 activity
in other experimental conditions [5,6], might also be rele-
vant to our present observation. Targeting mechanisms that
counter-regulate the spinal consequences of peripheral in-
flammation by CK1 inhibitors or other methods may pro-
vide an effective way to control chronic pain. Further
elucidation of CK1 signaling mechanisms including spatial
distribution of CK1 isoforms before and after inflammation
is considered to be critical in future clinical development
for directing the signaling pathways with small molecule
agents.
Conclusions
In summary, the present study suggests an important role
of CK1 in inflammatory pain symptoms. Although the
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remains elusive, CK1 inhibitors could be promising new
therapeutics for treating pain associated with inflamma-
tion as well as neuropathic pain.
Methods
In vitro kinase assay
The inhibitory effects of TG003 and IC261 against CK1
isoforms were tested using the QuickScout screening as-
sist mobility shift assay with the ATP concentration at
the Km (4.1 μM for CK1α, 6.3 μM for CK1γ1, 10 μM for
CK1γ2, 3.2 μM for CK1γ3, 7.7 μM for CK1δ, and 16 μM
for CK1ε; Carna Biosciences, Inc., Kobe, Japan). Detailed
information on the assay condition is available on the
website of Carna Biosciences (http://www.carnabio.com).
Full-length human CK1α, CK1γ1, CK1γ2, CK1γ3 and
catalytic domain of human CK1ε were expressed as N-
terminal GST-fusion protein using baculovirus system,
and purified by using glutathione sepharose chromatog-
raphy. Catalytic domain of CK1δ was expressed as N-
terminal GST-fusion protein in E. coli, and purified by
using glutathione sepharose chromatography.
Vector construction
PCR-amplified fragments of mCherry (Clontech) and
PER3 (Accession: NP_058515) were fused in-frame by
overlap-extension PCR method to generate mCherry-
PER3, respectively, as described previously [43] with
some modifications. The combined fragment was
inserted into pCAGIPuro vector, an IRES-based bicis-
tronic expression vector where the gene of interest and
a puromycin resistant gene are expressed from a single
mRNA, which enables almost all of the cells selected
with puromycin to express the gene product. PCR-
amplified fragments of FLAG-tagged CK 1δ (Acces-
sion: BC015775) and ε (Accession: BC006490) were
fused in-frame to the amino-terminus of EGFP via F2A
peptide sequence by overlap-extension PCR method,
which enables bicistronic expression of FLAG-tagged
CK1 isoforms and EGFP. The combined fragments
were inserted into pcDNA5/FRT/TO (Life Technolo-
gies). The reconstituted vector sequences are available
upon request.
Cell culture and transfection
Flp-In/T-REx HEK293 cell (Life Technologies) was
maintained in low glucose Dulbecco's modified Eagle's
medium (Nacalai Tesque, Kyoto, Japan) supplemented
with 10% fetal bovine serum (Nichirei Biosciences,
Tokyo, Japan), 100 units/ml of penicillin and 100 μg/ml
of streptomycin (Nacalai Tesque). Cells were transfected
with plasmid DNAs using polyethylenimine MAX (Poly-
sciences) as described previously [44], and then selected
with hygromycin B (Life Technologies) for pcDNA5/FRT/TO vectors and puromycin (Nacalai Tesque) for
pCAGIPuro vectors to establish the stable cell lines.PER3 nuclear translocation assay
HEK293 cells seeded in a density of 1 × 105 cells/dish in
polyethyleneimine-coated 35 mm glass bottom dishes
(MatTek, Ashland, MA) were cultured for 2 days. Cells
were pre-incubated with 0.1% dimethyl sulfoxide
(DMSO) containing 30 μM TG003, 30 μM TG001, or
1 μM PF-670462 (Merck, Darmstadt, Germany) for
1 hour at 37°C before expression of CK1δ or CK1ε was
induced with 1 μg/ml of doxycycline. After 8 hour incu-
bation with doxycycline at 37°C, cells were fixed with
10% Formaldehyde Neutral Buffer Solution (Nacalai Tes-
que) for 10 min at room temperature. Cells were washed
twice with PBS and then stained with 5 μg/ml of
Hoechst33342 (Dojindo, Kumamoto, Japan) in PBS for
30 min at room temperature. The Hoechst33342 solu-
tion was removed and cells were washed with PBS, and
stored in 1.5 ml PBS at 4°C in the dark until taking
fluorescent images on the Confocal Laser Scanning Bio-
logical Microscope FV10i (Olympus, Tokyo, Japan).
The fluorescent images were analyzed by the compart-
mental analysis algorithm predefined in Cellomics BioAp-
plications (Thermo Fisher Scientific, Waltham, MA). The
nuclear-cytoplasmic ratio of the mCherry-PER3 signal in-
tensity was quantified by dividing the mean average
mCherry intensity in the nuclear area defined as “circ” by
the mean average mCherry intensity of a “ring” around
this area, which covered a cytoplasmic region. The dis-
tance of the circ to the nuclear outline was 16 pixels. The
ring had a width of 4 pixels and a distance of 1 pixel from
the nuclear outline. The fluorescent image containing over
15 objects (cells) counted by the compartmental analysis
algorithm was used for analysis. The objects that were
under 650 of the mean average EGFP intensity in the nu-
clear area were excluded. Analysis data was exported into
Excel file for statistical analysis.Animals
Male C57BL/6 J mice (5 weeks old) were purchased
from Clea Japan, Inc. (Tokyo, Japan) and housed under
controlled temperature (24 ± 1°C) and humidity (55 ±
10%) with a 12-hour light-dark cycle with food and
water freely available. The animal experiments were ap-
proved by the Animal Care Committees of Tokyo Med-
ical and Dental University (approval No. 0090173) and
Kagoshima University (approval No. MD10053), and
were conducted in accordance with the ethical guidelines
for the study of experimental pain in conscious animals
published by the International Association of the Study of
Pain (1995) [45] and the European Communities Council
Directive of 24 November, 1986 (86/609/EEC).
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To produce acute and persistent inflammatory pain, carra-
geenan (2% lambda carrageenan in saline, 25 μl, Sigma, St.
Louis, MO) and complete Freund’s adjuvant (CFA, 25 μl,
Sigma) were injected into the plantar surface of the right
hindpaw under light halothane anesthesia, respectively
[46-49]. Control mice were treated with saline or incom-
plete Freund’s adjuvant (IFA, Sigma), respectively. Mech-
anical allodynia and thermal hyperalgesia were measured
using the Dynamic Plantar Aesthesiometer (Ugo Basile,
Comerio VA, Italy) and the Paw Thermal Stimulator
(UCSD, San Diego, CA, USA), respectively as described
[12]. In CFA model, these behavioral experiments were
conducted 3 days after the injection. Intrathecal (i.t.) injec-
tion was given in a volume of 5 μl by percutaneous punc-
ture through an intervertebral space at the level of the 5th
or 6th lumbar vertebra, according to a previously reported
procedure [12,50]. An investigator, who was unaware of
the drug treatment, performed all of the behavioral
experiments.
Immunoblot analysis
Six hours after carrageenan or saline injection, and 3 days
after CFA or IFA injection, mice were anesthetized with
sodium pentobarbital (50 mg/kg), and the lumbar spinal
cord and DRGs (L4-L6) were quickly removed. Each sam-
ple was homogenized in a lysis buffer [150 mM NaCl,
1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS, 1:100 diluted protease inhibitor cocktail (Sigma), and
50 mM Tris-HCl, pH 8.0]. Protein concentrations were
determined with a Bio-Rad protein assay kit (Bio-Rad,
Hercules, CA). Proteins were separated by SDS-PAGE
(7.5% gel) and then transferred to a polyvinylidene difluor-
ide membrane (Millipore, Billerica, MA). Anti-CK1α (rabbit
polyclonal, raised against amino acids 281-337 at the C-
terminus of human CK1α; 1: 2,000; no. sc-28886, Santa
Cruz Biotechnology, Santa Cruz, CA), anti-CK1ε (rabbit
polyclonal, raised against amino acids 301-360 near the C-
terminus of human CK1ε; 1: 1,000; no. sc-25423, Santa
Cruz Biotechnology) and anti-CK1δ antibody (rabbit poly-
clonal, NC10, 1:4,000; kindly donated by Prof. Uwe
Knippschild, Univ. Ulm, Germany) were used. The spec-
ificities of the three antibodies were characterized and
reported previously in several studies including ours
[12,41,42,51]. We have also conducted control staining
experiments; omission of primary antibody or secondary
antibody, and substitution of primary antibody with
normal rabbit IgG. We did not obtain any signals from
these control experiments (data not shown).
Immunoreactivity was detected by using the ECL
system (GE Healthcare, Buckinghamshire, UK). An anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) anti-
body (mouse monoclonal, 1:20,000; no. MAB374, Che-
micon, Temecula, CA) or β-actin (mouse monoclonal,1:1,000; no. sc-47778, Santa Cruz Biotechnology) were
used to normalize protein loading. Relative intensities of
the bands were quantified by using an image analysis
system with Image J software, version 1.40 g (National
Institutes of Health, Bethesda, MD). At least two inde-
pendent immunoblot experiments of three independent
spinal cord and DRG samples were analyzed.
Patch-clamp recordings from spinal dorsal horn neurons
Adult mouse spinal cord slices were prepared according
to the method of Yoshimura & Jessell [21,22]. Briefly,
6 hours after carrageenan or saline injection, and 3 days
after CFA or IFA injection, transverse slices (thickness,
800-900 μm) of the L5 spinal segments with the L5 dor-
sal root attached were cut on a vibrating blade micro-
tome. The slices were superfused with Krebs solution
(10-15 ml/min) saturated with 95% O2 and 5% CO2 at
36 ± 1°C. The composition of Krebs solution was as fol-
lows (in mM): NaCl 117; KCl 3.6; NaHCO3 25;
NaH2PO4 1.2; CaCl2 2.5; MgCl2 1.2, and glucose 11
(pH 7.4 after gas saturation).
Blind whole-cell patch-clamp recordings were made
from the lamina II (substantia gelatinosa: SG) neurons
ipsilateral to carrageenan, CFA, or vehicle (saline or IFA)
injection in voltage clamp mode. Patch pipettes were
fabricated from thin-walled, borosilicate, glass-capillary
tubing (1.5 mm o.d., World Precision Instruments).
After establishing the whole-cell configuration, neurons
were held at the potential of -70 mV to record spontan-
eous excitatory postsynaptic currents (sEPSCs) and at
the potential of 0 mV to record spontaneous inhibitory
postsynaptic currents (sIPSC). Under these conditions,
GABA- and glycine-mediated IPSCs and glutamate-
mediated EPSCs, respectively, were negligible, because
these holding potential were close to the reversal poten-
tials of IPSCs and EPSCs, respectively [52]. Recording
electrodes were filled with either potassium gluconate-
based solution (in mM: K-gluconate 135; KCl 5; CaCl2
0.5; MgCl2 2; EGTA 5; HEPES 5; ATP-Mg 5; adjusted
with KOH to pH 7.2) to investigate EPSCs, or Cs-based
solution (in mM: Cs2SO4 110; tetraethylammonium 5;
CaCl2 0.5; MgCl2 2; EGTA 5; HEPES 5; ATP-Mg 5; ad-
justed with CsOH to pH 7.2) to examine IPSCs. The re-
sistance of a typical patch pipette is 5-10 MΩ. Membrane
currents were amplified with an Axopatch 200B amplifier
(Molecular Devices, Sunnyvale, CA, USA) in voltage-
clamp mode. Signals were low-pass filtered at 5 kHz and
digitized at 333 kHz with an A/D converter (Digidata
1322, Molecular Devices). Data were stored with a per-
sonal computer using pCLAMP10 software and analyzed
with Mini Analysis software (Synaptosoft Inc., Decatur,
GA, USA).
The average values of both frequency and amplitude
of sEPSCs or sIPSCs during the control (1 min) and 5-
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attainment of steady effect of each drug) were calculated
and quantified as relative changes in frequency and amp-
litude. Since the characteristics of sEPSCs and sIPSCs
parameters (frequency and amplitude) were not signifi-
cantly different among naïve-, saline- and IFA-control,
data from each control were combined.Drugs
IC261 was from Calbiochem, LaJolla, CA, USA. PF-670462
was obtained from Tocris bioscience, Bristol, UK. TG003
and TG001 were synthesized according the procedures
described previously [13]. These drugs were made up as
concentrated stock solution in DMSO, aliquoted and
stored at –20°C. An aliquot was diluted to the desired
concentration in saline or Krebs solution immediately
prior to use. The dose ranges of IC261 and TG003 used
were determined according to our previous report (for
IC261) [12] and preliminary study (for TG003).Statistical analysis
Experimental data are expressed as mean ± SEM. Single
comparisons were made using Student’s two-tailed
paired or unpaired t-test. One-way ANOVA followed by
the Dunnett’s or Tukey’s test was used for multiple com-
parisons. P < 0.05 was considered statistically significant.Additional files
Additional file 1: Carrageenan- and CFA-induced inflammation did
not upregulate CK1α, δ and ε expression. Immunoblot analyses of
CK1α (A), δ (B) and ε (C) expression levels in the spinal cord and DRGs.
L4-6 spinal segments and DRGs ipsilateral to the inflammation were
dissected 6 hours after carrageenan (Car) and 3 days after CFA injection.
As a control, saline (Sal) and incomplete Freund’s adjuvant (IFA) were
injected instead of Car and CFA, respectively.
Additional file 2: Comparison of passive membrane properties
among L5 SG neurons obtained from control and inflamed mice.
Additional file 3: Effects of inflammation on spontaneous EPSCs
(sEPSCs, A) and IPSCs (sIPSCs, B). Hindpaw injection of CFA but not
carrageenan (Car) increased mean frequency of sEPSCs and decreased
mean frequency of sIPSCs. Neither CFA nor carrageenan changed mean
amplitudes of sEPSCs and sIPSCs. Three days (CFA 3d) or 6 hours (Car
6 h) after injection, spinal cord slices were prepared and blind whole-cell
patch-clamp recordings were made from the SG neurons ipsilateral to
Car, CFA, or vehicle injection. *P < 0.05, **P < 0.01; one-way ANOVA
followed by Tukey’s post hoc test.Abbreviations
CFA: Complete Freund’s adjuvant; CK: Casein kinase; Clk: cdc2-like kinase;
DRG: Dorsal root ganglion; GAPDH: Glyceraldehyde-3-phosphate
dehydrogenase; IFA: Incomplete Freund’s adjuvant; i.t.: Intrathecal;
sEPSC: Excitatory and inhibitory postsynaptic currents; sIPSC: Inhibitory
postsynaptic currents; SG: Substantia gelatinosa.Competing interests
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